Chemotherapy News and Research

Latest Chemotherapy News and Research

Click chemistry advances precision oncology by merging imaging and therapyly

Conventional cancer treatments like chemotherapy often struggle with poor targeting, leading to severe systemic toxicity and drug resistance.

19 May 2026

Molecular profiling initiative seeks to uncover late breast cancer recurrence mysteries

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), in collaboration with the SWOG Cancer Research Network (SWOG), has launched a new initiative to analyze paired original and recurrent tumor specimens from two practice-changing breast cancer clinical trials.

19 May 2026

Blood test detects tumor DNA to guide advanced cancer treatment

A blood test that detects tumor DNA circulating in the bloodstream may help select the most effective treatment options for cancer patients whose tumors have started to spread, according to one of the largest randomized controlled trials of its kind presented at the Congress of the European Society for Radiotherapy and Oncology (ESTRO 2026).

18 May 2026

Targeted radiotherapy may delay progression in metastatic breast cancer patients

Treating breast cancer that has begun to spread around the body with targeted radiotherapy could help patients to live longer without their cancer getting worse, according to the results of a small randomised controlled trial presented at the Congress of the European Society for Radiotherapy and Oncology (ESTRO 2026).

17 May 2026

Cancer-driving MYC protein also helps tumors repair damaged DNA

A protein best known for driving cancer growth also helps damaged tumor cells survive by repairing their DNA, according to a new study that could influence how some cancers are treated.

17 May 2026

Multi-institutional trial explores new lifeline for advanced prostate patients

For men with advanced prostate cancer that no longer responds to standard hormone therapies, treatment options are limited – and time matters. As the disease progresses, the window for effective, less intensive treatments begins to close.

15 May 2026

Study reveals why aging makes the body more vulnerable to breast cancer

Researchers at Georgetown's Lombardi Comprehensive Cancer Center have identified a mechanism that may help explain a key reason why older people experience worse outcomes from breast cancer.

15 May 2026

Scientists develop a dual action strategy to destabilize the COVID virus

An unprecedented study led by researchers at the University of Malaga proposes a new antiviral strategy against SARS-CoV-2 -the virus responsible for causing COVID-19 disease- based on a treatment that combines two complementary approaches, capable of attacking the virus simultaneously, forcing its instability and hindering its ability to adapt.

14 May 2026

Gene panel predicts chemotherapy response in triple-negative breast cancer

Researchers at The University of Texas MD Anderson Cancer Center have characterized cancer cell-specific features in the tumor microenvironment (TME) of early-stage triple-negative breast cancer (TNBC) tissues, identifying specific macrophage subtypes associated with chemotherapy response.

13 May 2026

Next-generation cancer therapy shows early promise as treatment candidate for glioblastoma

A next-generation cancer therapy being developed at McMaster University has shown early promise as a treatment candidate for glioblastoma, the most aggressive and most common type of primary brain cancer in adults.

13 May 2026

Study explains how APOE2 gene protects the brain against Alzheimer's disease

People who carry the APOE2 version of the apolipoprotein E gene are more likely to live to advanced age and are partly protected against Alzheimer's disease, but scientists have struggled to explain why.

13 May 2026

Study compares two antibiotics in treating severe hemorrhagic bacterial pneumonia

Stenotrophomonas maltophilia (S. maltophilia) is a multidrug-resistant bacterium that can cause severe and life-threatening hemorrhagic pneumonia in individuals with weakened immune systems.

11 May 2026

New study reveals how slow-growing cells drive breast cancer relapse

A new study by the Garvan Institute of Medical Research has uncovered a hidden mechanism explaining why breast cancer can return many years after successful treatment.

11 May 2026

Study challenges assumptions about testosterone’s role in brain cancer

Scientists have long suspected that androgens, male sex hormones like testosterone, may help tumors grow because the hormones can suppress immune responses to some cancers.

8 May 2026

New nanoparticles disable drug resistance to achieve complete tumor elimination

Cancer cells frequently develop the ability to expel anticancer drugs before they can work -- a phenomenon called multidrug resistance (MDR) -- which is one of the leading reasons why chemotherapy fails in patients.

8 May 2026

Diverse leukemia stem cells may drive AML relapse after therapy

Scientists from the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute have deciphered a key mechanism that contributes to treatment failure in acute myeloid leukemia (AML).

7 May 2026

Scientists identify powerful human antibodies capable of neutralizing measles virus

Scientists at La Jolla Institute for Immunology (LJI) are the first in the world to characterize human antibodies capable of neutralizing measles virus.

7 May 2026

Many metastatic lung cancer patients still receive no treatment options

About half of people diagnosed with metastatic non-small-cell lung cancer never receive treatment, despite advances in options over recent decades that have created meaningful improvements in lifespan and quality of life for many patients.

7 May 2026

A new combined therapy to boost the immune system against cancer

Cancer immunotherapy is built on a simple but powerful idea: the immune system can recognize and destroy cancer cells if it is properly activated. In many patients, however, this response is too weak or too slow to be effective.

7 May 2026

Targeted RAS inhibitor shows promise against pancreatic cancer mutations

The targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard treatments for patients with RAS-mutant pancreatic cancer, according to results of a Phase 1/2 trial led by researchers at The University of Texas MD Anderson Cancer Center.

7 May 2026